Pharmaceutical Business review

GSK to deploy BioClinica Trident IWR across Phase I-IV clinical trials

BioClinica‘s Trident IWR’s design provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials, in a fraction of the time previously required.

BioClinica claims that its Trident IWR delivers rapid study setup without the need for programming, while simultaneously delivering world-class IVR (Interactive Voice Response) system phone support through the same simplified configuration process.

BioClinica CEO Mark Weinstein said that GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident.

"We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies," Weinstein said.